On #IWD2026, we recognize the women who have made progress on behalf of patients worldwide, including our team, who are building a company at the forefront of tackling diseases by modulating RNA with small molecules and addressing disease drivers at their source. #RemixTherapeutics

Welcome Chip Michaud, Vice President of Finance, & Hayley Amemiya, Senior Scientist, Bioinformatics & Data Science, to Remix! Their leadership and experience will help us advance our next stage of growth addressing the intractable drivers of disease.
#RemixTherapeutics

Today, we announced the appointment of Mythili Koneru, MD, PhD, as our Chief Medical Officer, leading clinical development, medical strategy, and regulatory engagement.

#mRNA #RNAdegradation #RNAdegraders #RNAtherapeutics #OncologyResearch #RemixTherapeutics

Read the PR here: bit.ly/4qJply4

Remix will be attending the upcoming virtual RBC Capital Markets Healthcare Private Company Conference. Our CEO, Pete Smith, will be presenting on Dec 11th at 1:20 PM and will be joined by, CBO, Heather Wasserman, for investor meetings. #RBCHealthcare #RemixTherapeutics

Our CSO, Dom Reynolds, PhD, will be highlighting the development of REM-422 for ACC, AML, and high-risk MDS and how our REMaster™ platform is advancing RNA-targeted drug discovery at the 8th RNA-Targeted Drug Discovery & Development Summit. #REM422 #mRNA #RemixTherapeutics

Our CEO, Pete Smith, PhD, will be attending the London Growth Summit, hosted by LifeSci Capital and
Sofinnova Partners. Pete Smith, PhD, CEO, and Heather Wasserman, CBO, will be attending Jefferies
Global Healthcare Conference. #JefferiesHealthcare #RemixTherapeutics

Our Co-Founder and CEO, Pete Smith, and Chief Business Officer, Heather Wasserman, will be participating in the Wells Fargo Virtual Private Biopharma Symposium on November 5.
If you would like to schedule a meeting, please reach out to: info@remixtx.com. #RemixTherapeutics

Join us next week for the @bloodcancerunited.bsky.social Light the Night Boston! We will be walking with thousands of others to honor those affected by blood cancers for greater awareness, research & support. #LightTheNight #LLS #RemixTherapeutics
Learn more: bit.ly/3VVRuo8

Remix CEO and Co-Founder, Pete Smith will be taking part in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference in Boston next week. #RemixTherapeutics